Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
RESEARCH TOOLSreports
Total Valuation
Structure Therapeutics, Inc. Sponsored ADR has a market cap or net worth of $1.55B. The enterprise value is $1.60B.
Market Cap$1.55B
Enterprise Value$1.60B
Share Statistics
Structure Therapeutics, Inc. Sponsored ADR has 57,536,750 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,536,750
Owned by Insiders11.71%
Owned by Institutions47.13%
Financial Efficiency
Structure Therapeutics, Inc. Sponsored ADR’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -18.25%.
Return on Equity (ROE)-0.14
Return on Assets (ROA)-0.14
Return on Invested Capital (ROIC)-18.25%
Return on Capital Employed (ROCE)-0.18
Revenue Per Employee0.00
Profits Per Employee-751.69K
Employee Count163
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Structure Therapeutics, Inc. Sponsored ADR is -43.01. Structure Therapeutics, Inc. Sponsored ADR’s PEG ratio is -8.60.
PE Ratio-43.01
PS Ratio0.00
PB Ratio6.09
Price to Fair Value6.09
Price to FCF-44.68
Price to Operating Cash Flow-45.18
PEG Ratio-8.60
Income Statement
In the last 12 months, Structure Therapeutics, Inc. Sponsored ADR had revenue of 0.00 and earned -122.53M in profits. Earnings per share was -0.21.
Revenue0.00
Gross Profit0.00
Operating Income-158.23M
Pretax Income-122.22M
Net Income-122.53M
EBITDA-158.23M
Earnings Per Share (EPS)-0.21
Cash Flow
In the last 12 months, operating cash flow was -116.58M and capital expenditures -1.29M, giving a free cash flow of -117.87M billion.
Operating Cash Flow-116.58M
Free Cash Flow-117.87M
Free Cash Flow per Share-2.05
Dividends & Yields
Structure Therapeutics, Inc. Sponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.45
52-Week Price Change-29.91%
50-Day Moving Average20.68
200-Day Moving Average31.33
Relative Strength Index (RSI)73.82
Average Volume (3m)1.11M
Important Dates
Structure Therapeutics, Inc. Sponsored ADR upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Structure Therapeutics, Inc. Sponsored ADR as a current ratio of 24.74, with Debt / Equity ratio of 0.45%
Current Ratio24.74
Quick Ratio24.74
Debt to Market Cap<0.01
Net Debt to EBITDA1.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Structure Therapeutics, Inc. Sponsored ADR has paid 310.00K in taxes.
Income Tax310.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Structure Therapeutics, Inc. Sponsored ADR EV to EBITDA ratio is -98.86, with an EV/FCF ratio of -132.65.
EV to Sales0.00
EV to EBITDA-98.86
EV to Free Cash Flow-132.65
EV to Operating Cash Flow-134.12
Balance Sheet
Structure Therapeutics, Inc. Sponsored ADR has $883.52M in cash and marketable securities with $621.00 in debt, giving a net cash position of -$879.66M billion.
Cash & Marketable Securities$883.52M
Total Debt$621.00
Net Cash-$879.66M
Net Cash Per Share-$15.29
Tangible Book Value Per Share$1.48
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Structure Therapeutics, Inc. Sponsored ADR is $83.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$83.88
Price Target Upside210.67% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast7.57%